Work in progressForm renders, but the Run button is not yet wired to the orchestrator. Note also: per the Carvykti dual-VHH toxicity case study (architecture §2.2), dual-binder constructs amplify both efficacy and tonic-signaling risk — design choices here should be informed by that.
Design dual-VHH CAR-T constructs with three architectures: LNP-delivered in vivo reprogramming, bispecific tandem CARs, or a hybrid combining both strategies.
Architecture
Disease Target
Antigen Preset
Design Tool
Number of Designs: 100
10500
T-Cell Target
T-Cell Marker
Design Tool
Number of Designs: 100
10500
Construct Components
Signal Peptide
Hinge
Transmembrane
Costimulatory
Signaling
info
Scientific questions pending expert review
Open review items for this construct type can be accessed via the API at /api/v1/car/reviews.
Configuration Summary
ArchitectureIn Vivo LNP Delivery
Disease TargetCD19
T-Cell TargetCD3ε
Signal PeptideCD8α
HingeCD8α
TransmembraneCD8α
Costimulatory4-1BB
SignalingCD3ζ (3 ITAM)